Physician profile
Hasina Hamid
NPI 1033356829
$3,479.47
in general payments reported to CMS, 2019-2025
26 companies · $1,490 in 2025
The $1,490 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $184 · 2023: $606 · 2024: $1,199 · 2025: $1,490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,267 · Education: $27.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,267.28 |
| Education | $27.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $609.05 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $380.56 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $377.66 | 2022-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $344.74 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $342.18 | 2023-2025 | |
| Abbvie INC. | $314.03 | 2023-2025 | |
| Astellas Pharma US INC | $196.38 | 2023-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $171.81 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.84 | 2022-2024 | Jardiance, Tradjenta |
| Otsuka America Pharmaceutical, INC. | $77.05 | 2022-2024 | Rexulti |
| Merck Sharp & Dohme LLC | $60.50 | 2023-2025 | Belsomra, Verquvo, Gardasil 9 |
| Janssen Pharmaceuticals, INC | $60.06 | 2023 | Xarelto |
| Exact Sciences Corporation | $54.70 | 2023-2024 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $54.52 | 2024-2025 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $42.60 | 2023-2024 | Voquezna |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.00 | 2023-2025 | Xifaxan, Trulance |
| Daiichi Sankyo INC. | $38.95 | 2025 | Injectafer |
| Novartis Pharmaceuticals Corporation | $38.45 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.88 | 2025 | |
| Dexcom, INC. | $29.84 | 2025 | Dexcom G6 Transmitter |
| Hologic Sales and Service, LLC | $24.69 | 2024 | Aptima |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.20 | 2025 | Caplyta |
| Boston Scientific Corporation | $20.62 | 2023 | Varithena Administration Pack |
| Takeda Pharmaceuticals U.S.A., INC. | $15.29 | 2024 | Trintellix |
| Tris Pharma INC | $14.85 | 2024 | Dyanavel Xr |
| Abbott Laboratories | $12.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hasina Hamid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.